advanced or recurrent gastric cancer
Conditions
Interventions
continuous infusion of 5-fluorouracil
combination of irinotecan and cisplatin
oral administration of S-1
Sponsors
Japan Clinical Oncology Group(JCOG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) unresectable or recurrent histologically proved gastric cancer 2) adequate oral intake 3) age 20 or older and 75 or younger 4) Performance Status (ECOG):0, 1, 2 5) measurable or unmeasurable lesions 6) preserved organ functions 7) no esvere medical condition 8) no prior chemotherapy for gastric cancer 9) written informed consent
Exclusion criteria
Exclusion criteria: 1) patient with marked infection or inflammation 2) patient with severe peritoneal metastasis 3) patient with massive plueral effusion 4) patient with metastasis to CNS 5) patiet with diarrhea 4 or more times per day 6) patient severe medical condition 7) patient with other concurrent malignancy affecting on survival or adverse events 8) pregnant or nursing patient or with intent to bear baby 9) patient evaluated to be inadequate by a attending doctor 10) patient reqiring nutritional support
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| time to treatment failure, incidences of adverse events, response rate, non-hospitalized survival | — |
Countries
Japan
Contacts
Public ContactNarikazu Boku, MD
JCOG9912 Coordinating Office Div. of Gastrointestinal Oncology, Shizuoka Cancer Center
Outcome results
None listed